-
Brahman Sired ARS,
Brooksville cattle (344 animals)
*
Brahman sires, Brahman dams
-
Charolais Sired CMP**
cattle (435 animals)
*
Charolais sires, Black Angus dams
-
Brangus Sired CMP**
cattle
* Brangus sires, primarily Brangus and some Brangus cross dams
-
Red Angus Sired CMP**
cattle
* Red Angus sires, mostly Red Angus dams, some crossbred
-
Black Angus Sired CMP**
cattle
* Black Angus sires, Black Angus dams
-
Australian CRC 1
Indicus-influenced (~ 650 Animals)
* Santa Gertrudis and Belmont Red
-
Australian CRC 2
Indicus-influenced (747 animals)
* Brahman, Senepol and Belmont Red infused composites
-
Australian CRC 1
Brahmans (~150 Animals)
* Purebred Brahman
-
Australian CRC 2
Brahmans (700 animals)
* Purebred Brahman
-
Commercial US cattle
population (1364 animals)
-
* Purebred and crossbred offspring of 285 sires from the following breeds:
202 Angus, 7 Red Angus, 6 Charolais, 7 Gelbveh , 4 Horned
Hereford , 11 Polled Hereford, 4 Limousin , 7 Simmental, 1 Braford,
3 Shorthorn, 12 were of mixed breed, and 21 were of unknown
breed. Cows were: 360 Angus, 6 Red Angus, 11 Charolais, 2 Horned Hereford , 5 Polled Hereford, 2 Limousin, 9
Simmental, 15 Shorthorn, 598 were crossbred cows, and 356 were
of unknown breed composition.
North American Angus validation population
(~760 bulls, steers and heifers)
* Purebred Angus
North American Bos taurus “Pfizer A***” validation population (~671
bulls, heifers and steers)
* European Maternal Line Composite Bulls, finished on ad lib feed
for greater than 40 days, 100 – 130 days on feed
North American Bos
taurus “Pfizer B***” validation population (~785 steers)
* European Maternal Line Composite Steers, 150 – 180 days on feed
North American Bos indicus-influenced “Pfizer C***” validation
population (~395 steers)
* Equal percentage of Simbrah, Red Brangus and Braford maternal
line composites.
** CMP =
carcass merit project; influential sires in their breed in the
1990s were utilized ("legacy bulls")
*** Letter-designations for validation populations as described
in Pfizer Technical Summary (February 2009)
